SCHEMBL20914116

SCHEMBL20914116

COc1cccc2oc(-c3c(C)[nH]c4c(-c5cccnc5)c(C(F)(F)F)nn4c3=O)nc12

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.33
▸ TNKS O95271 1/20 0.33
▸ TNKS2 Q9H2K2 1/20 0.33
▸ PARP2 Q9UGN5 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ PPARG P37231 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ APLNR P35414 3/20 0.33
▸ F2RL3 Q96RI0 3/20 0.33
▸ MAPT P10636 2/20 0.32
▸ PIK3CD O00329 1/20 0.32
▸ PIK3CB P42338 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ PDE10A Q9Y233 1/20 0.31
▸ CA12 O43570 1/20 0.31
▸ CA1 P00915 1/20 0.31
▸ CA2 P00918 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20819069 0.91 TNKS (0.37) KDM4ETNKSTNKS2PARP2POLB
SCHEMBL20913957 0.89 TNKS (0.34) KDM4ETNKSTNKS2PARP2POLB
SCHEMBL20931264 0.89 TNKS (0.39) TNKSTNKS2PARP2F2RL3MAPT
SCHEMBL20837034 0.89 TNKS (0.39) KDM4ETNKSTNKS2PARP2POLB
SCHEMBL20913911 0.88 HPGD (0.35) KDM4ETNKSTNKS2PARP2MEN1
SCHEMBL20914067 0.88 ARF6 (0.35) KDM4ETNKSTNKS2PARP2F2RL3
SCHEMBL20914062 0.88 TNKS (0.39) KDM4ETNKSTNKS2PARP2MEN1
SCHEMBL20914030 0.87 PSEN1 (0.35) KDM4ETNKSTNKS2PARP2MEN1
SCHEMBL20914243 0.86 F2RL3 (0.35) TNKSTNKS2PARP2F2RL3MAPT
SCHEMBL20914037 0.86 TSHR (0.39) TNKSTNKS2PARP2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 KDM4E 1922/4885TNKS 531/4885TNKS2 932/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 KDM4E 1922/4885TNKS 531/4885TNKS2 932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback